The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP

The poor prognosis of HNSCC is partly due to treatment resistance. The SMAC mimetic Xevinapant is a promising new approach to targeted cancer therapy. Xevinapant inhibits cIAP1/2 and XIAP, leading to apoptosis, necroptosis and inhibition of prosurvival signaling. Combining Xevinapant with IR could i...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Julia, Hildebrand, Laura S., Kuhlmann, Lukas, Fietkau, Rainer, Distel, Luitpold V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297233/
https://www.ncbi.nlm.nih.gov/pubmed/37371123
http://dx.doi.org/10.3390/cells12121653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297233/
https://www.ncbi.nlm.nih.gov/pubmed/37371123
http://dx.doi.org/10.3390/cells12121653

Ejemplares similares